---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-233693"
form_type: "8-K"
ticker: "FDMT"
cik: "0001650648"
company_name: "4D Molecular Therapeutics, Inc."
filed_at: "2023-09-13T23:59:59+00:00"
generated_at: "2026-06-10T19:08:06.330657+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CFO August Moretti retires; Uneek Mehra appointed as CFO effective Sept 11, 2023

## Summary
- August J. Moretti retired as CFO effective Sept 11, 2023; will serve as Senior Business Advisor through 2023 then consultant through Dec 2024 at $18k/month.
- Uneek Mehra appointed CFO, Principal Financial and Accounting Officer; base salary $510k, target bonus 45%, option grant of 229,634 shares.
- Mehra previously served as CFO at Myovant Sciences (Sept 2021-July 2023) and PACT Pharma.
- Sign-on bonus of $200k in two installments; severance includes 9 months base salary and COBRA reimbursement.

## SEC filing metadata
- accession: 0001193125-23-233693
- form_type: 8-K
- ticker: FDMT
- cik: 0001650648
- company_name: 4D Molecular Therapeutics, Inc.
- filed_at: 2023-09-13T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650648/000119312523233693/0001193125-23-233693-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650648/000119312523233693/d387807d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-233693
- JSON: https://secwatch.observer/filing/0001193125-23-233693.json
- Plain text: https://secwatch.observer/filing/0001193125-23-233693.txt

## Key facts
- Executive change
  Uneek Mehra was appointed as Chief Financial and Business Officer at 4D Molecular Therapeutics, Inc..
  - Action: joined
  - Role: Chief Financial and Business Officer
  source text: announced that Uneek Mehra had joined the Company as Chief Financial and Business Officer, Principal Financial Officer, Principal Accounting Officer, and Assistant Secretary of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1650648/000119312523233693/0001193125-23-233693-index.htm
- Executive change
  August J. Moretti departed as Chief Financial Officer at 4D Molecular Therapeutics, Inc..
  - Action: retire
  - Role: Chief Financial Officer
  source text: announced that August J. Moretti will retire as Chief Financial Officer and Assistant Secretary of the Company, effective September 11, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1650648/000119312523233693/0001193125-23-233693-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.